TENNECO CANADA, INC. (ALBRIGHT & WILSON AMERICAS DIVISION) – Trademark Portfolio
Entity Type: 03
TENNECO CANADA, INC. (ALBRIGHT & WILSON AMERICAS DIVISION) holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 1 filings in this category. Currently, 1 trademark is registered. Notable registered marks include ERCOCIDE. The owner is based in ISLINGTON, ONTARIO.
2 GIBBS ROAD
ISLINGTON, ONTARIO M9B 1R1 , CA
Showing of trademarks Trademarks
Trademark Classifications
TENNECO CANADA, INC. (ALBRIGHT & WILSON AMERICAS DIVISION)'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does TENNECO CANADA, INC. (ALBRIGHT & WILSON AMERICAS DIVISION) have?
TENNECO CANADA, INC. (ALBRIGHT & WILSON AMERICAS DIVISION) has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.
What trademark classes does TENNECO CANADA, INC. (ALBRIGHT & WILSON AMERICAS DIVISION) file in?
TENNECO CANADA, INC. (ALBRIGHT & WILSON AMERICAS DIVISION) files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are TENNECO CANADA, INC. (ALBRIGHT & WILSON AMERICAS DIVISION)'s most well-known trademarks?
TENNECO CANADA, INC. (ALBRIGHT & WILSON AMERICAS DIVISION)'s registered trademark portfolio includes well-known marks such as ERCOCIDE. These are among 1 currently registered trademark in the portfolio.
What is TENNECO CANADA, INC. (ALBRIGHT & WILSON AMERICAS DIVISION)'s trademark registration success rate?
TENNECO CANADA, INC. (ALBRIGHT & WILSON AMERICAS DIVISION) has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.